GTTX Stock Overview
A biopharmaceutical company, focuses on the development of precision gene editing therapies based on its GeneTether platform for human therapeutics applications. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
GeneTether Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.08 |
| 52 Week High | CA$0.11 |
| 52 Week Low | CA$0.015 |
| Beta | 2.07 |
| 1 Month Change | -20.00% |
| 3 Month Change | 433.33% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -88.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| GTTX | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 77.8% | -3.6% | -2.6% |
| 1Y | n/a | 12.9% | 15.2% |
Return vs Industry: Insufficient data to determine how GTTX performed against the Canadian Biotechs industry.
Return vs Market: Insufficient data to determine how GTTX performed against the Canadian Market.
Price Volatility
| GTTX volatility | |
|---|---|
| GTTX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 13.4% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CA Market | 17.4% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: GTTX's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: Insufficient data to determine GTTX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Roland Boivin | genetether.com |
GeneTether Therapeutics Inc., a biopharmaceutical company, focuses on the development of precision gene editing therapies based on its GeneTether platform for human therapeutics applications. It is developing gene therapies for the treatment of patients with rare and monogenic kidney and skin diseases. The company was founded in 2018 and is based in Kelowna, Canada.
GeneTether Therapeutics Inc. Fundamentals Summary
| GTTX fundamental statistics | |
|---|---|
| Market cap | CA$3.10m |
| Earnings (TTM) | -CA$1.00m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.1x
P/E RatioIs GTTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GTTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$696.96k |
| Earnings | -US$696.96k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.018 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GTTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 04:27 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GeneTether Therapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|